Related by context. All words. (Click for frequent words.) 79 IMC #B 76 HGS ETR1 74 HGS ETR2 74 pertuzumab 73 investigational humanized monoclonal antibody 73 MGCD# [001] 73 ganetespib 73 mapatumumab 73 HGS# 72 Blinatumomab 71 alvespimycin 71 Panzem R NCD 71 PXD# 71 Phase Ib II 70 Perifosine 70 receptor tyrosine kinase inhibitor 70 INCB# [001] 70 enzastaurin 70 Proxinium TM 70 Sapacitabine 70 axitinib 70 seliciclib 70 Imprime PGG 70 PEG SN# 70 phase IIb trial 70 ixabepilone 70 T DM1 70 lintuzumab 70 phase IIb clinical 70 Archexin 70 Phase #b/#a 70 PSN# [002] 70 MGd 70 anti leukemic 70 BAY #-# 70 AEG# 70 XmAb# 70 YONDELIS 69 SAR# [004] 69 antibody MAb 69 sorafenib Nexavar ® 69 oral prodrug 69 erlotinib Tarceva ® 69 HuMax EGFr 69 Carfilzomib 69 Pralatrexate 69 PSMA ADC 69 CYC# 69 elotuzumab 69 obatoclax 69 sunitinib malate 69 Omacetaxine 69 mertansine 69 Aplidin 69 IAP inhibitor 69 Annamycin 69 tanespimycin 69 Cloretazine 69 HCD# [002] 69 investigational monoclonal antibody 69 Trastuzumab DM1 68 orally administered inhibitor 68 docetaxel Taxotere R 68 BRAF inhibitor 68 cilengitide 68 BZL# 68 MEK inhibitors 68 Phase Ib clinical trials 68 forodesine 68 OXi# 68 talabostat 68 neratinib 68 targeting CD# 68 Amrubicin 68 anti EGFR antibody 68 dacetuzumab 68 Elotuzumab 68 AP# [003] 68 CD# antibody [001] 68 bevacizumab Avastin ® 68 cediranib 68 phase Ib 68 ENMD # 68 CA4P 68 HER2 positive metastatic breast 68 Aplidin R 68 motesanib 68 Enzastaurin 68 HuMax CD# 68 fosbretabulin 68 belinostat 68 Aflibercept 67 galiximab 67 IMA# 67 liposomal formulation 67 evaluating tivozanib 67 Exherin TM 67 ZOLINZA 67 JAK inhibitors 67 huC# DM4 67 MDV# 67 Tyrima 67 radiation sensitizer 67 vemurafenib 67 PDE4 inhibitor 67 AEGR 67 metastatic hormone refractory 67 CYT# potent vascular disrupting 67 Phase IIb trials 67 HuLuc# 67 CR# vcMMAE 67 Ocrelizumab 67 IL# PE#QQR 67 Bortezomib 67 pomalidomide 67 Seliciclib 67 deforolimus 67 Xanafide 67 Phase Ib clinical 67 docetaxel Taxotere ® 67 MAGE A3 ASCI 67 selective modulator 67 TACI Ig 67 Pertuzumab 67 OMP #M# 67 Panzem NCD 67 nab paclitaxel 67 oblimersen 67 vascular disrupting agents 67 CBLC# 67 Phase Ib 67 AAG geldanamycin analog 67 antitumor activity 67 oral deforolimus 67 Phase Ib study 67 paclitaxel Taxol ® 66 glufosfamide 66 MAb 66 vidofludimus 66 DAVANAT 66 Zolinza 66 Vitaxin 66 Phase IIb clinical trials 66 sorafenib Nexavar 66 FOLFOX6 chemotherapy regimen 66 Nanobody 66 BRIM2 66 trastuzumab Herceptin R 66 eniluracil 66 cetuximab Erbitux R 66 Dapagliflozin 66 ZK EPO 66 otelixizumab 66 metaglidasen 66 Bezielle 66 TELCYTA 66 rNAPc2 66 dasatinib Sprycel ® 66 CCX# 66 evaluating Xcytrin 66 Voreloxin 66 entinostat 66 Symadex 66 Cloretazine ® 66 Azedra 66 Gleevec resistant 66 Talabostat 66 tubulin inhibitor 66 Phase #b/#a clinical 66 Golimumab 66 relapsed multiple myeloma 66 phase IIb 66 alpha folate receptor 66 sapacitabine 66 Trastuzumab 66 farletuzumab 66 multi kinase inhibitor 66 JAK inhibitor 66 GV# [001] 66 cathepsin K inhibitor 66 immunomodulator 66 Alfimeprase 66 multitargeted 66 Laquinimod 66 refractory chronic lymphocytic 66 Degarelix 66 targeted antifolate 66 milatuzumab 66 Panitumumab 66 Ceflatonin 66 IgG1 monoclonal antibody 66 vandetanib 66 Vilazodone 66 human IgG1 monoclonal 66 Chemophase 66 JAK2 inhibitor 66 Pazopanib 66 NXL# 66 multicenter Phase II 66 DXL# 66 rALLy clinical trial 66 GRN#L 66 sorafenib Nexavar R 66 ARRY # 66 CYT# 66 vorinostat 66 HDACi 66 uric acid lowering 66 Sym# 66 AQ4N 65 PI3K/Akt pathway inhibitor 65 Virulizin ® 65 Quinamed 65 RG# [001] 65 sodium glucose cotransporter 65 VNP#M 65 Phase 2b Clinical Trial 65 decitabine 65 depsipeptide 65 GVAX 65 FOLOTYN ® 65 Tesetaxel 65 Targretin 65 LY# [003] 65 epothilone 65 elacytarabine 65 Pimavanserin 65 dose escalation Phase 65 vascular disrupting agent 65 preclinically 65 TBC# 65 GAP #B# 65 relapsed refractory multiple myeloma 65 JAK1 65 Vandetanib 65 bortezomib Velcade R 65 Deforolimus 65 Phase 2b clinical trials 65 potent antiproliferative 65 Omnitarg 65 OncoVEX GM CSF 65 Curaxin CBLC# 65 HDAC Inhibitor 65 Akt inhibitor 65 cetuximab Erbitux ® 65 Tarvacin TM 65 OMP #R# 65 iniparib 65 Asentar 65 carboplatin paclitaxel 65 IAP inhibitors 65 Aurora Kinase 65 Glufosfamide 65 gefitinib Iressa 65 Panzem R 65 aflibercept VEGF Trap 65 Phase 1b 65 Traficet EN 65 heavily pretreated 65 vinca alkaloid 65 ISTODAX 65 PLX# 65 orally bioavailable 65 SUTENT 65 nucleoside analog 65 GMX# 65 #D#C# 65 TRO# 65 Tarceva TM 65 ErbB 65 drug conjugate 65 CIMZIA TM 65 cetuximab Erbitux 65 trastuzumab DM1 65 LymphoStat B belimumab 65 MDS AML 65 Allovectin 7 R 65 apoptosis inducer 65 metastatic HRPC 65 voreloxin 65 LEP ETU 65 paclitaxel poliglumex 65 Oral NKTR 65 TELINTRA 65 pharmacodynamic effects 65 TRV# [001] 65 ASONEP 65 registrational trial 65 GRN# 65 IMGN# 65 refractory metastatic 65 IgG1 antibody 65 anticancer compound 65 R#/MEM # 65 MT#/MEDI-# 65 indibulin 65 Phase 1b clinical trials 65 proteasome inhibitors 65 Universal Flu Vaccine 65 Allovectin 7 ® 65 Alocrest 65 vosaroxin 65 brentuximab vedotin SGN 65 AVE# 65 MEK inhibitor 65 daclizumab 65 Ixempra 65 aflibercept 65 Xelox 65 Erbitux cetuximab 64 angiogenesis inhibitor 64 antiangiogenic therapy 64 ADP receptor antagonist 64 dasatinib Sprycel 64 refractory AML 64 Telcyta 64 dose cohorts 64 Bicifadine 64 IRX 2 64 gemcitabine Gemzar 64 ELACYT 64 PNP inhibitor 64 trastuzumab DM1 T DM1 64 Phase IIb Clinical Trial 64 monoclonal antibody IgG1 Mab 64 DU #b 64 xenograft models 64 tesmilifene 64 TOCOSOL Camptothecin 64 SCH # 64 sorafenib tablets 64 huN# DM1 64 NPC 1C 64 multicenter Phase 64 PEG Interferon lambda 64 PI3K/mTOR 64 dose escalation 64 docetaxel chemotherapy 64 Phase 1b trial 64 cannabinor 64 panitumumab Vectibix 64 platinum refractory 64 pegylated liposomal doxorubicin 64 Exelixis compounds 64 EGFR inhibitors 64 Apaziquone 64 lintuzumab SGN 64 VEGF inhibitors 64 virus HCV protease inhibitor 64 EOquin 64 receptor inhibitor 64 HGS ETR1 mapatumumab 64 demonstrated antitumor activity 64 ponatinib 64 Allovectin 7 64 JAK3 64 antibody MT# 64 TG# [003] 64 EndoTAG TM -1 64 tezampanel 64 thymalfasin 64 CD# monoclonal antibody 64 hormone LHRH antagonist 64 recurrent metastatic ovarian cancer 64 Phase IIa trial 64 PKC# 64 ascending dose 64 Romidepsin 64 nucleoside reverse transcriptase inhibitor 64 AKT inhibitor 64 epigenetic therapies 64 phase IIa clinical 64 immunotherapeutic agent 64 humanised monoclonal antibody 64 Cloretazine R VNP#M 64 trial evaluating PRX# 64 Neulasta ® 64 IMiDs R 64 Onconase 64 myelofibrosis polycythemia vera 64 erlotinib Tarceva 64 Lu AA# 64 proteasome inhibitor 64 Clofarabine 64 Phase 2a trial 64 novel VDA molecule 64 c MET 64 adecatumumab 64 nilotinib Tasigna ® 64 Maribavir 64 Abiraterone acetate 64 Epothilone D 64 Marqibo 64 Pivotal Phase III 64 OvaRex R 64 chemotherapy FOLFOX 64 Afatinib 64 Phase III Clinical Trials 64 SUCCEED trial 64 Vicinium TM 64 standard chemotherapy regimen 64 DermaVir Patch 64 cMET 64 Herceptin trastuzumab 64 HuMax CD4 64 midstage trials 64 panobinostat 64 Pivotal Phase 64 DACH platinum 64 BN# [002] 64 Fludara ® 64 alefacept 64 RGB # 64 Amigal 64 Cannabinor 64 teriflunomide 64 EFAPROXYN 64 Iloperidone 64 lymphoid malignancies 64 zalutumumab 64 Atiprimod 64 MetMAb 64 Granulocyte Colony Stimulating Factor 64 visilizumab 64 favorable pharmacokinetic profile 64 PRTX 64 Mipomersen 64 Ridaforolimus 64 anticancer therapy 64 Hsp# Inhibitor 64 TOCOSOL Paclitaxel 64 tramiprosate Alzhemed TM 64 mTOR inhibitors 64 Irinotecan 64 pan HDAC inhibitor 64 novel tubulin binding 64 AZD# 64 Denufosol 64 XL# [003] 64 adalimumab Humira 64 protein kinase inhibitor 64 Factor VIIa 64 ulimorelin 64 CLORETAZINE TM VNP#M 64 Aurora kinase inhibitor 64 Azacitidine 64 TMC# [002] 64 Xcytrin 64 investigational protease inhibitor 64 Randomized Phase 64 mTOR inhibitor 64 L Annamycin 64 CORT # 64 APTIVUS 64 OncoVEX 64 TriRima 64 Ofatumumab 64 HCV protease 64 histone deacetylase inhibitor 64 sapacitabine CYC# 64 topotecan 63 oral ridaforolimus 63 accumulate preferentially 63 Velcade bortezomib 63 class mGluR5 inhibitor 63 Phase 2b trial 63 Neuvenge 63 LUX Lung 63 Phase IIB 63 sunitinib 63 ritonavir boosted 63 Pemetrexed 63 PI3K inhibitor 63 XL# XL# XL# XL# 63 small molecule tyrosine 63 Angiocept 63 molecularly targeted 63 mecamylamine 63 Meets Primary Endpoint 63 CD4 monoclonal antibody 63 CDK inhibitor 63 EGFr 63 seliciclib CYC# 63 signal transduction inhibitor 63 MGCD# [002] 63 BMS # 63 TRX1 63 Onrigin 63 evaluating satraplatin 63 bortezomib Velcade 63 CoFactor 63 MKC# MKC# PP 63 VAPRISOL 63 MKC# MT 63 TKB# 63 rituximab Rituxan 63 Ozarelix 63 antitumor effects 63 pharmacokinetic PK 63 EGFR TKI 63 systemic ALCL 63 romidepsin 63 liposomal doxorubicin 63 Folfox 63 Daclizumab 63 TNFα 63 riociguat 63 signal transduction inhibitors 63 triggers apoptosis programmed 63 PF # [001] 63 sunitinib Sutent 63 EndoTAGTM 1 63 StemEx 63 pralatrexate 63 olaparib 63 lenalidomide Revlimid R 63 YONDELIS R 63 Tanespimycin 63 pharmacokinetics pharmacodynamics 63 ACTEMRA TM 63 GLPG# 63 Safinamide 63 rindopepimut 63 PRT# 63 anti amnesic 63 Aurora kinase 63 regorafenib 63 immunomodulating 63 Multimeric 63 glucagon receptor 63 Rigel R# 63 non nucleoside inhibitor 63 tremelimumab 63 humanized anti 63 tumor vascular disrupting 63 midstage clinical 63 selective kinase inhibitor 63 imatinib Gleevec 63 FGFR 63 thalidomide Thalomid 63 chimeric monoclonal antibody 63 BRIM3 63 EOquin TM 63 Zybrestat 63 antiangiogenic 63 Vorinostat 63 idarubicin 63 therapeutic monoclonal antibody 63 humanized monoclonal antibody 63 temsirolimus 63 Phase 2a Clinical Trial 63 atacicept 63 CB2 selective receptor agonist 63 cytokine refractory 63 novel anticancer 63 prostate cancer AIPC 63 standard chemotherapy regimens 63 humanized antibody 63 HSP# inhibitor 63 TAFA# 63 lapatinib Tykerb 63 SAR# [002] 63 MORAb 63 Immunotherapeutic 63 Gemzar ® 63 agonistic human 63 immune modulating 63 pharmacodynamic PD 63 PI3K inhibitors 63 metastatic renal cell carcinoma 63 imatinib Gleevec ® 63 PARP inhibitor 63 CEQ# 63 Advaxis Phase 63 ORENCIA R 63 cytoprotective 63 Troxatyl 63 anticancer therapies 63 mTOR mammalian target 63 Actilon 63 sunitinib Sutent ® 63 KRN# 63 Temsirolimus 63 Elagolix 63 cell lymphoma CTCL 63 Squalamine 63 systemic anaplastic large 63 AMD# [003] 63 ZYBRESTAT fosbretabulin 63 PANVAC VF 63 pharmacodynamic markers 63 follicular NHL 63 dose cohort 63 R roscovitine 63 TLR9 agonist 63 hypoxia inducible factor 63 Arranon 63 A3 adenosine receptor 63 Personalized Immunotherapy 63 Phase IIa trials 63 bortezomib 63 orally dosed 63 metastatic colorectal 63 castrate resistant prostate cancer 63 tolerability pharmacokinetics 63 peptibody 63 ASG 5ME 63 mGluR5 NAM 63 PI3K Akt 63 Alemtuzumab 63 Sudhir Agrawal D.Phil 63 estramustine 63 ZACTIMA 63 VEGF receptor 63 investigational pan BCR 63 Epratuzumab 63 anticancer agent 63 darapladib 63 Tasimelteon 63 Hedgehog Pathway Inhibitor 63 novel peptide 63 PHX# 63 CRx 63 recurrent glioblastoma multiforme 63 Vidofludimus 63 ATL# [001] 63 dexpramipexole 63 selective androgen receptor modulator 63 DEB# 63 Insegia 63 HDAC inhibitor 63 trastuzumab emtansine T DM1 63 HCV protease inhibitors 63 unique alkylating agent 63 Phase III Pivotal 63 Rituxan rituximab 63 refractory prostate cancer 63 OncoVex 63 Kinase Inhibitor 63 GLP toxicology studies 63 kinase inhibition 63 HDAC inhibition 63 drug pipeline TAFA# 63 corticosteroid dexamethasone 63 immune modulatory 63 pramlintide metreleptin combination 63 lenalidomide dexamethasone 63 Nexavar sorafenib 63 heavily pretreated patients 63 EZN 63 PrevOnco ™ 63 Tamibarotene 63 Tykerb lapatinib 63 ISIS # 63 oral anticancer 63 randomized Phase 2b 62 oxaliplatin Eloxatin 62 lumiliximab 62 Telintra 62 abiraterone acetate 62 castration resistant prostate cancer 62 microtubule inhibitor 62 hA# 62 Urocidin 62 Xeloda ® 62 oral antiviral 62 bendamustine 62 volociximab 62 cancer immunotherapies 62 velafermin 62 blinded randomized placebo controlled 62 Telavancin 62 tyrosine kinase inhibitor 62 FLT3 62 Hormone Refractory Prostate Cancer 62 pharmacodynamics 62 targeted radiotherapeutic 62 EGFR tyrosine kinase inhibitors 62 5 FU leucovorin 62 PRX # 62 ASA# 62 Clolar ® 62 metastatic RCC 62 Cethromycin 62 OncoGel 62 Dasatinib 62 Pivotal Trial 62 Ambrisentan 62 TYZEKA 62 T#I [002] 62 biologic therapy 62 YERVOY 62 NSCLC tumors 62 Bafetinib 62 MYDICAR ® 62 NP2 Enkephalin 62 Triapine 62 ANG# 62 elvitegravir 62 AeroLEF TM 62 xanthine oxidase inhibitor 62 PEG PAL 62 Genasense ® 62 Vidaza azacitidine 62 diabetic neuropathic pain 62 FOLFOX chemotherapy 62 sipuleucel T 62 generation purine nucleoside 62 hematologic malignancies 62 Taxotere docetaxel 62 carfilzomib 62 5 HT6 receptor 62 rxRNA 62 CD# expressing 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 PDX pralatrexate 62 torezolid phosphate 62 Hsp# inhibition 62 afatinib 62 TO AVOID PREGNANCY WHILE 62 pharmacodynamic profiles 62 Vectibix 62 Taxotere chemotherapy 62 CRLX# 62 perifosine 62 novel histone deacetylase 62 Factor Xa inhibitor 62 topoisomerase II inhibitor 62 Milatuzumab 62 Darusentan 62 Curaxin 62 ThermoDox R 62 dextromethorphan quinidine 62 Novolimus 62 ALN TTR 62 trastuzumab Herceptin 62 pharmacokinetic PK study 62 Fx #A 62 BCR ABL inhibitors 62 delafloxacin 62 Fludara 62 long acting muscarinic 62 ESBA# 62 EndoTAG 62 HCV SPRINT 62 GW# [003] 62 Campath alemtuzumab 62 Cetrorelix 62 GRNVAC1 62 5 fluorouracil leucovorin 62 IMP# 62 FOLFOX6 62 brostallicin 62 histone deacetylase HDAC inhibitor 62 candidate CRLX# 62 valopicitabine 62 Angiolix 62 bortezomib Velcade ® 62 selective orally bioavailable 62 Revlimid lenalidomide 62 amrubicin 62 resistant ovarian cancer 62 MyVax R 62 relapsed ovarian cancer 62 refractory chronic myeloid 62 XYOTAX TM 62 retaspimycin 62 investigational therapies 62 TREANDA 62 Evoltra ® 62 custirsen 62 Elesclomol 62 bosutinib 62 GALNS 62 Anticalin 62 CIMZIA ™ 62 ARIKACE ™ 62 PhG alpha 1 62 pharmacodynamic profile 62 K ras mutations 62 dose escalation trial 62 mda 7 62 Pharmacokinetics PK 62 efficacy tolerability 62 bevacizumab Avastin 62 poly ADP ribose polymerase 62 OvaRex ® MAb 62 IGF IR 62 immunomodulatory 62 HQK 62 Phase #/#a trial 62 mTOR kinase 62 polymerase inhibitor 62 Platinol 62 telomerase therapeutic 62 tezampanel NGX# 62 trabectedin 62 ruxolitinib 62 oral picoplatin 62 Gemcitabine 62 LHRH antagonists 62 luteinizing hormone releasing 62 cleavable linker 62 Kahalalide F 62 ofatumumab HuMax CD# 62 evaluating picoplatin 62 HRPC 62 EGFR HER2 62 Factor Receptor 62 CCR9 antagonist 62 Nexavar ® 62 low dose cytarabine 62 Epidermal Growth Factor Receptor 62 NOX E# 62 Preclinical studies suggest 62 Lenocta 62 CG# [003] 62 randomized Phase 62 Etoposide 62 CTLA 4 62 anticancer agents 62 Intravenous CP 62 refractory multiple myeloma 62 alkylating agent 62 5 HT2A receptor 62 EGF receptor 62 hypoxia activated prodrug 62 preclinical efficacy 62 XOMA 3AB 62 relapsed MM 62 effector function 62 combinability 62 veltuzumab 62 bicifadine 62 gemcitabine carboplatin 62 Antibody Drug Conjugate 62 Phase #b/#a trial 62 apoptosis proteins 62 paclitaxel Taxol 62 Ipilimumab 62 lupus nephritis 62 HER pathway 62 IMiDs ® 62 bevacizumab Avastin R 62 ALK inhibitor 62 DOXIL 62 Vidaza ® 62 registrational 62 MCSP respectively 62 PSN# [001] 62 2 methoxyestradiol 62 LymphoStat B TM 62 INCB# [003] 62 investigational compounds 62 MEK Inhibitor 62 Vectibix panitumumab 62 ON #.Na 62 Bavituximab 62 alfa 2a 62 immunomodulatory therapy 62 tolerated dose MTD 62 omega interferon 62 compound INCB# 62 PrevOnco 62 Motesanib 62 Phase IIb Trial 62 CCR9 62 cyclin dependent kinases CDKs 62 JAK2 inhibitors 62 Serdaxin ® 62 somatostatin analogue 62 VEGFR2 inhibitor 62 Tyrosine Kinase Inhibitor 62 including eniluracil ADH 62 Phase III Clinical Trial 62 evaluating T DM1 62 SERMs 62 Anti Tumor 62 APTIVUS r 62 Methylnaltrexone 62 Combination REOLYSIN R 62 Bevacizumab 62 ganaxolone 62 Zarnestra 62 LBH# 62 budesonide foam 62 NS4A 62 investigational immunotherapy 62 Nanobody ® 62 Elvitegravir 62 Antitumor Activity 62 Jevtana 62 TLR8 agonist 62 refractory CLL 62 IIa trial 62 Fc fusion protein 62 Tezampanel 62 celgosivir 62 Phase 2b study 62 TTF Therapy 62 Randomized Phase II 62 dacetuzumab SGN 62 non nucleoside HCV 62 insulin sensitizers 61 Thiarabine 61 Rituximab 61 paclitaxel Taxol R 61 immune stimulatory 61 potent cytotoxic 61 trodusquemine 61 oral rivaroxaban 61 Advanced Renal Cell 61 pegylated interferons 61 Erlotinib 61 chemotherapeutic drug 61 Epothilones 61 BNC# 61 Anticalins R 61 antiangiogenic agents 61 subcutaneous formulation 61 posaconazole 61 selectively inhibits 61 leukemia AML 61 CanAg 61 taxane 61 aurora kinase 61 Doxil ® 61 GED aPC 61 selectively inhibit 61 Taxol paclitaxel 61 JVRS 61 gemcitabine Gemzar ® 61 safety tolerability pharmacokinetic 61 Ixabepilone 61 relapsed refractory 61 Bosutinib 61 Antiviral Activity 61 temozolomide 61 Spiegelmer ® 61 TLK# 61 THR beta agonist 61 Thiovir 61 hematological cancers 61 XL# XL# XL# 61 GVAX ® 61 placebo controlled Phase 61 pro angiogenic 61 MNTX 61 HIF 1a 61 daunorubicin 61 #ME# 61 interferon gamma 1b 61 CTAP# Capsules 61 goserelin 61 PEGylated Fab fragment 61 Antiangiogenic 61 peripherally acting 61 Synavive 61 Advexin 61 CDK cyclin dependent 61 Camptosar ® 61 melphalan prednisone 61 kinase inhibitor 61 Saxagliptin 61 autologous cellular immunotherapy 61 SNT MC# 61 talactoferrin 61 RAV# 61 acyclovir Lauriad R 61 oncolytic 61 sitaxsentan 61 Pathway Inhibitor 61 trastuzumab Herceptin ® 61 CHOP chemotherapy 61 small molecule chemotherapeutic 61 RhuDex R 61 histone deacetylase HDAC 61 dose escalation clinical 61 biliary tract cancer 61 TOLAMBA 61 Cutaneous T 61 Phase 2b Study 61 Gefitinib 61 indolent NHL 61 Viramidine 61 XL# XL# 61 UPLYSO 61 systemic RNAi therapeutic 61 metastatic malignant melanoma 61 Smac mimetic 61 Fulvestrant 61 delta opioid receptor 61 M2 subunit 61 alpha#beta# integrin 61 Genz # 61 interleukin IL -# 61 anti angiogenic agent 61 neurotrophic 61 elesclomol